{"id":"gallium-ga-68-dotatate","rwe":[{"pmid":"41281034","year":"2025","title":"Optimising Gallium-68 (⁶⁸Ga) DOTATATE PET/CT Reconstruction in Neuroendocrine Tumours: A Paired Comparison of Penalised-Likelihood (BSREM/Q.Clear) and Ordered Subset Expectation Maximisation Algorithms.","finding":"","journal":"Cureus","studyType":"Clinical Study"},{"pmid":"41064857","year":"2025","title":"(68)Ga-DOTATATE Measurements Predict Progression of Aortic Valve Calcification in Humans.","finding":"","journal":"Arteriosclerosis, thrombosis, and vascular biology","studyType":"Clinical Study"},{"pmid":"39613415","year":"2024","title":"Remission of longstanding metastatic paraganglioma in a patient after use of zoledronic acid.","finding":"","journal":"BMJ case reports","studyType":"Clinical Study"},{"pmid":"39137605","year":"2024","title":"(68)Ga-DOTATATE PET/CT: How is it reliable in imaging of cases having clinical suspicion of insulinomas?","finding":"","journal":"European journal of radiology","studyType":"Clinical Study"},{"pmid":"39006730","year":"2024","title":"Occult Pancreatic Neuroendocrine Tumor Presenting as Carcinoid Syndrome.","finding":"","journal":"Cureus","studyType":"Clinical Study"}],"tags":[{"label":"Active","category":"status"},{"label":"Mayo Clinic","category":"company"}],"phase":"phase_2","safety":{},"trials":[],"aliases":["(68)Ga-DOTA-TATE","68Ga-DOTA-0-Tyr3-Octreotate","68Ga-DOTATATE","Gallium Ga 68 Oxodotreotide","Gallium Oxodotreotide Ga-68"],"company":"Mayo Clinic","patents":[],"pricing":[],"offLabel":[],"timeline":[],"ecosystem":[],"mechanism":{"explanation":"Imagine a key that fits into a specific lock. Gallium Ga 68-DOTATATE is like that key, designed to bind to specific molecules in the body. This binding allows doctors to use imaging tests to see where the key is located, which can help diagnose and monitor certain conditions.","oneSentence":"Gallium Ga 68-DOTATATE works by binding to specific targets in the body, allowing for diagnostic imaging.","technicalDetail":"Gallium Ga 68-DOTATATE is a small molecule that uses the radiolabel gallium-68 to bind to somatostatin receptors, which are found on certain types of cells in the body. This binding allows for diagnostic imaging using positron emission tomography (PET) scans."},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=Gallium%20Ga%2068-DOTATATE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gallium Ga 68-DOTATATE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:19:04.181461","biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"gallium ga 68-dotatate","indications":{"approved":[{"name":"Positron emission tomography","diseaseId":"positron-emission-tomography","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT02019706","phase":"PHASE2","title":"Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2014-02-12","conditions":["ACTH","Cushing's Syndrome"],"enrollment":80,"completionDate":"2030-12-31"},{"nctId":"NCT05691465","phase":"PHASE2","title":"Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-12-27","conditions":["Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation","Metastatic Prostate Neuroendocrine Carcinoma","Metastatic Prostate Small Cell Neuroendocrine Carcinoma","Stage IV Prostate Cancer AJCC v8"],"enrollment":30,"completionDate":"2026-11-02"},{"nctId":"NCT06991738","phase":"PHASE1,PHASE2","title":"177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2026-04-01","conditions":["Thyroid Cancer"],"enrollment":18,"completionDate":"2032-08-01"},{"nctId":"NCT00001160","phase":"","title":"Studies on Tumors of the Thyroid","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"1977-06-01","conditions":["Hurthle Cell Thyroid Cancer","Tall Cell Variant Thyroid Cancer","Follicular Thyroid Cancer","Thyroid Cancer","Papillary Thyroid Cancer"],"enrollment":2500,"completionDate":""},{"nctId":"NCT04804371","phase":"NA","title":"Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2021-03-04","conditions":["Neuroendocrine Tumors"],"enrollment":40,"completionDate":"2027-02-22"},{"nctId":"NCT04927416","phase":"PHASE2","title":"The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2021-10-25","conditions":["Metastic Thyroid Cancer"],"enrollment":54,"completionDate":"2030-11-30"},{"nctId":"NCT07472049","phase":"","title":"Symptomatic and Systemic Atherosclerotic Plaque Activity in Patients With Peripheral Arterial Disease Using Novel Imaging","status":"RECRUITING","sponsor":"University of Edinburgh","startDate":"2025-07-31","conditions":["Peripheral Arterial Disease","Chronic Limb Threatening Ischemia"],"enrollment":100,"completionDate":"2029-07"},{"nctId":"NCT06379217","phase":"PHASE1","title":"NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-07-29","conditions":["Metastatic Neuroendocrine Prostate Cancer"],"enrollment":31,"completionDate":"2026-08-27"},{"nctId":"NCT06427798","phase":"PHASE1,PHASE2","title":"Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-02-07","conditions":["Somatostatin Receptor Positive","Gastrointestinal Neuroendocrine Tumors","Pheochromocytoma","Paragangliomas"],"enrollment":66,"completionDate":"2039-07-01"},{"nctId":"NCT07150546","phase":"PHASE1","title":"Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-10-14","conditions":["Digestive System Neuroendocrine Tumor","Unresectable Digestive System Neuroendocrine Neoplasm","Unresectable Digestive System Neuroendocrine Tumor G1","Unresectable Digestive System Neuroendocrine Tumor G2"],"enrollment":15,"completionDate":"2027-09-30"},{"nctId":"NCT04298541","phase":"PHASE2","title":"Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC","status":"NOT_YET_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2026-06","conditions":["Meningioma"],"enrollment":6,"completionDate":"2027-06"},{"nctId":"NCT04074135","phase":"PHASE2","title":"Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-06-02","conditions":["VHL Pancreatic Neuroendocrine Tumors","Von Hippel-Lindau Disease","Neuroendocrine Tumors"],"enrollment":740,"completionDate":"2036-07-01"},{"nctId":"NCT03206060","phase":"PHASE2","title":"Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-10-10","conditions":["Pheochromocytoma","Paraganglioma","Neuroendocrine Tumors","Neuroendocrine Neoplasms"],"enrollment":130,"completionDate":"2033-01-01"},{"nctId":"NCT06500065","phase":"NA","title":"68Ga-DOTATATE PET/CT for the Diagnosis of Soft Tissue Sarcomas","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2024-09-30","conditions":["Soft Tissue Sarcoma"],"enrollment":30,"completionDate":"2026-12-31"},{"nctId":"NCT07366099","phase":"NA","title":"Al18F-NOTA-LM3 PET/CT in Patients With TIO","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-03-30","conditions":["Tumor-Induced Osteomalacia"],"enrollment":40,"completionDate":"2026-05-30"},{"nctId":"NCT07353229","phase":"PHASE1","title":"68Ga-Dotatate PET and MRI Guided Radiation Dose Escalation for High Risk Meningioma","status":"SUSPENDED","sponsor":"Thomas Jefferson University","startDate":"2025-09-05","conditions":["High Risk Meningioma","Recurrent Meningioma"],"enrollment":24,"completionDate":"2028-09"},{"nctId":"NCT07350707","phase":"PHASE1,PHASE2","title":"Diagnostic Value of CXCR4-targeted PET/CT in ACTH-dependent and Independent Cushing's Syndrome","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-06-12","conditions":["Cushing s Syndrome"],"enrollment":160,"completionDate":"2027-02-12"},{"nctId":"NCT04040088","phase":"EARLY_PHASE1","title":"An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2019-09-23","conditions":["Ganglioneuroblastoma","Ganglioneuroma","Neuroblastoma"],"enrollment":20,"completionDate":"2026-07"},{"nctId":"NCT07150806","phase":"PHASE1,PHASE2","title":"RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma","status":"RECRUITING","sponsor":"Joshua Palmer","startDate":"2025-11-12","conditions":["Recurrent Meningioma"],"enrollment":30,"completionDate":"2026-12-31"},{"nctId":"NCT07288931","phase":"NA","title":"Al18F-NOTA-LM3 PET/CT in Patients With Pheochromocytoma and Paraganglioma","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-08-06","conditions":["Pheochromocytoma/Paraganglioma (PPGL)"],"enrollment":40,"completionDate":"2026-03-01"},{"nctId":"NCT07284589","phase":"PHASE2","title":"Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake","status":"RECRUITING","sponsor":"Akiva Mintz","startDate":"2025-12-11","conditions":["Healthy (Controls)","Healthy Volunteers","Neuroendocrine (NE) Tumors"],"enrollment":200,"completionDate":"2030-04-30"},{"nctId":"NCT04082520","phase":"PHASE2","title":"Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2020-04-14","conditions":["Grade 1 Meningioma","Grade 2 Meningioma","Grade 3 Meningioma","Recurrent Meningioma","Unresectable Meningioma"],"enrollment":41,"completionDate":"2031-01-06"},{"nctId":"NCT04069299","phase":"","title":"Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-09-25","conditions":["Neuroendocrine Carcinoma"],"enrollment":30,"completionDate":"2026-01"},{"nctId":"NCT02743741","phase":"NA","title":"Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2016-07-15","conditions":["Neuroendocrine Tumors"],"enrollment":195,"completionDate":"2026-06"},{"nctId":"NCT06479811","phase":"PHASE1","title":"[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-08-19","conditions":["Head and Neck Tumors","Kidney Cancers","Small Cell Lung Cancers","Pheochromocytoma/Paragangliomas","Gastrointestinal Neuroendocrine Tumors","Somatostatin Receptor Positive"],"enrollment":120,"completionDate":"2032-01-01"},{"nctId":"NCT04081701","phase":"PHASE4","title":"68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.","status":"RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2019-09-04","conditions":["CNS Tumors","Meningioma","Esthesioneuroblastoma","Hemangioblastoma","Medulloblastoma","Paraganglioma","Pituitary Adenoma"],"enrollment":200,"completionDate":"2038-12-31"},{"nctId":"NCT04529044","phase":"PHASE2","title":"177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-12-01","conditions":["Anatomic Stage IV Breast Cancer AJCC v8","Metastatic Breast Carcinoma","Recurrent Breast Carcinoma"],"enrollment":10,"completionDate":"2026-12-20"},{"nctId":"NCT07195500","phase":"","title":"Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/Paraganglioma","status":"RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2024-12-25","conditions":["Neuroblastoma","Pheochromocytoma","Paraganglioma"],"enrollment":30,"completionDate":"2028-06-30"},{"nctId":"NCT06256705","phase":"NA","title":"Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-03-25","conditions":["Gastroenteropancreatic Neuroendocrine Tumor","Radiotherapy"],"enrollment":80,"completionDate":"2029-09-25"},{"nctId":"NCT04609592","phase":"PHASE1","title":"Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery","status":"RECRUITING","sponsor":"Stanford University","startDate":"2021-03-17","conditions":["Gastroenteropancreatic Neuroendocrine Tumor"],"enrollment":10,"completionDate":"2027-09"},{"nctId":"NCT07119242","phase":"PHASE3","title":"Evaluate the Diagnostic Efficacy, Pharmacokinetics and Safety of 68Ga-DOTATATE Injection PET/CT in NETs","status":"ACTIVE_NOT_RECRUITING","sponsor":"HTA Co., Ltd.","startDate":"2024-01-08","conditions":["NETs"],"enrollment":95,"completionDate":"2025-12-31"},{"nctId":"NCT01879657","phase":"NA","title":"68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs)","status":"COMPLETED","sponsor":"Radio Isotope Therapy of America","startDate":"2013-03-01","conditions":["Neuroendocrine Carcinoma"],"enrollment":169,"completionDate":"2017-12-05"},{"nctId":"NCT03448458","phase":"PHASE2","title":"Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Emory University","startDate":"2018-02-22","conditions":["Castration-Resistant Prostate Carcinoma","Metastatic Prostate Carcinoma","Stage IV Prostate Cancer AJCC v7"],"enrollment":17,"completionDate":"2023-02-06"},{"nctId":"NCT03576040","phase":"","title":"Whole Body Dynamic 68Ga-DOTATOC PET/CT in Neuroendocrine Tumors","status":"COMPLETED","sponsor":"University Hospital, Brest","startDate":"2018-07-19","conditions":["Neuroendocrine Tumors"],"enrollment":120,"completionDate":"2023-07-06"},{"nctId":"NCT03583528","phase":"","title":"DOTATOC PET/CT for Imaging NET Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"British Columbia Cancer Agency","startDate":"2018-07-11","conditions":["Neuroendocrine Tumors","Insulinoma","Gastrinoma","Glucagonoma","Vipoma","Pheochromocytoma","Paraganglioma","Neuroblastoma","Ganglioneuroma","Medullary Carcinoma","Pituitary Adenoma","Medulloblastoma","Merkel Cell Carcinoma","Small-cell Lung Cancer","Meningioma","Carcinoid"],"enrollment":800,"completionDate":"2028-09-30"},{"nctId":"NCT06091748","phase":"PHASE3","title":"Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-02-22","conditions":["Advanced Gastroenteropancreatic Neuroendocrine Tumor"],"enrollment":66,"completionDate":"2025-11-01"},{"nctId":"NCT06455358","phase":"PHASE1,PHASE2","title":"61Cu-NODAGA-LM3 PET/CT for the Detection of Neuroendocrine Tumors (COPPER PET in NET)","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2025-02-05","conditions":["Neuroendocrine Tumors"],"enrollment":27,"completionDate":"2028-06"},{"nctId":"NCT02840149","phase":"PHASE3","title":"SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine Tumors","status":"COMPLETED","sponsor":"Jewish General Hospital","startDate":"2019-10-01","conditions":["Neuroendocrine Tumors"],"enrollment":45,"completionDate":"2023-12-13"},{"nctId":"NCT04544098","phase":"EARLY_PHASE1","title":"Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-09-02","conditions":["Neuroendocrine Tumors","Liver-Dominant Metastatic Pancreatic Neuroendocrine Tumors"],"enrollment":10,"completionDate":"2026-09"},{"nctId":"NCT03736564","phase":"PHASE1,PHASE2","title":"Ga-DOTATATE PET for Phosphaturic Mesenchymal Tumors in Patients With Tumor Induced Osteomalacia","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2019-01-31","conditions":["Osteomalacia"],"enrollment":18,"completionDate":"2023-10-31"},{"nctId":"NCT06800430","phase":"","title":"Graft Failure and Consequences of Coronary Artery Bypass Graft Surgery","status":"RECRUITING","sponsor":"University of Edinburgh","startDate":"2025-03-28","conditions":["Coronary Artery Bypass","Graft Failure","Coronary Artery Bypass Graft","Coronary Artery Bypass Graft Surgery (CABG)"],"enrollment":70,"completionDate":"2027-08-06"},{"nctId":"NCT06056362","phase":"PHASE1,PHASE2","title":"Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroendocrine Tumors","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-03-23","conditions":["Neuroendocrine Tumors"],"enrollment":80,"completionDate":"2025-03-27"},{"nctId":"NCT03602911","phase":"PHASE2","title":"A Comparison of NETSPOT Imaging Versus F-FDG-PET in Head and Neck Cancer Patients","status":"COMPLETED","sponsor":"West Virginia University","startDate":"2019-02-01","conditions":["Head and Neck Squamous Cell Carcinoma"],"enrollment":20,"completionDate":"2021-04-01"},{"nctId":"NCT06611891","phase":"PHASE3","title":"Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast Cancer","status":"RECRUITING","sponsor":"University Hospital, Grenoble","startDate":"2025-01-06","conditions":["Breast Cancer Metastatic"],"enrollment":25,"completionDate":"2026-10"},{"nctId":"NCT06773624","phase":"NA","title":"Use of 68Ga-DOTATOC PET/CT-enterography for Detection of the Primary Lesion in Neuroendocrine Tumors of the Small Bowel","status":"RECRUITING","sponsor":"European Institute of Oncology","startDate":"2021-04-23","conditions":["Small Bowel Neoplasia","Neuroendocrine (NE) Tumors"],"enrollment":18,"completionDate":"2026-12"},{"nctId":"NCT06188468","phase":"NA","title":"ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Solid Tumors","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2023-10-01","conditions":["Tumor","Solid Tumor","Positron-Emission Tomography"],"enrollment":90,"completionDate":"2024-08-31"},{"nctId":"NCT05183555","phase":"PHASE2","title":"Early Feasibility Study of Somatostatin Receptors PET Imaging for the Diagnosis of Infective Endocarditis","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2022-05-16","conditions":["Infective Endocarditis"],"enrollment":14,"completionDate":"2024-06-18"},{"nctId":"NCT04559217","phase":"PHASE2","title":"68Ga-DOTATATE Neuroblastoma Imaging Pilot","status":"RECRUITING","sponsor":"Centre de recherche du Centre hospitalier universitaire de Sherbrooke","startDate":"2021-12-06","conditions":["Neuroblastoma"],"enrollment":20,"completionDate":"2027-09-30"},{"nctId":"NCT06520319","phase":"PHASE1","title":"Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET/CT in Patients With Medullary Thyroid Carcinoma","status":"RECRUITING","sponsor":"First Affiliated Hospital of Fujian Medical University","startDate":"2023-06-21","conditions":["Medullary Thyroid Carcinoma"],"enrollment":20,"completionDate":"2025-07"},{"nctId":"NCT06226987","phase":"","title":"Molecular Imaging in Fabry Disease of the Heart","status":"RECRUITING","sponsor":"University of Cambridge","startDate":"2024-01-02","conditions":["Fabry Disease, Cardiac Variant"],"enrollment":12,"completionDate":"2026-01-02"},{"nctId":"NCT01873248","phase":"EARLY_PHASE1","title":"Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2013-08-26","conditions":["Neuroendocrine Tumors"],"enrollment":100,"completionDate":"2017-06-16"},{"nctId":"NCT04073797","phase":"NA","title":"PET Imaging of Inflammation and Lipid Lowering Study","status":"RECRUITING","sponsor":"University of Cambridge","startDate":"2023-03-20","conditions":["Hypercholesterolemia","Hypercholesterolemia, Familial","Atherosclerosis","Carotid Artery Plaque"],"enrollment":63,"completionDate":"2026-03-01"},{"nctId":"NCT04073810","phase":"","title":"Residual Inflammation and Plaque Progression Long-term Evaluation","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Cambridge","startDate":"2020-10-01","conditions":["Atherosclerosis","Myocardial Infarction","Coronary Artery Disease","Inflammation"],"enrollment":40,"completionDate":"2025-04-01"},{"nctId":"NCT04412369","phase":"","title":"Multi-modality Imaging & Immunophenotyping of COVID-19 Related Myocardial Injury","status":"COMPLETED","sponsor":"University of Cambridge","startDate":"2020-07-01","conditions":["COVID19","Cardiovascular Diseases"],"enrollment":21,"completionDate":"2023-08-01"},{"nctId":"NCT04847505","phase":"PHASE3","title":"68Ga-DOTA-TATE PET/CT Imaging in NETs","status":"RECRUITING","sponsor":"Centre de recherche du Centre hospitalier universitaire de Sherbrooke","startDate":"2020-01-01","conditions":["Neuroendocrine Tumors"],"enrollment":5000,"completionDate":"2025-12-31"},{"nctId":"NCT06467968","phase":"NA","title":"Heart Analysis in GATED-PET in Patients Having a Gallium-68-DOTATOC PET/CT Exam for Oncology Indication","status":"RECRUITING","sponsor":"Central Hospital, Nancy, France","startDate":"2023-02-02","conditions":["Cardiac Inflammation"],"enrollment":99,"completionDate":"2025-08-26"},{"nctId":"NCT05478733","phase":"","title":"Study of Factors Associated With Significant MYoCArdian Uptake on 68Ga-DOTATOC PET Scans for Oncology","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2022-09-01","conditions":["Oncologic Disorders"],"enrollment":210,"completionDate":"2023-07-01"},{"nctId":"NCT06359054","phase":"NA","title":"The Role of 68GA DOTATATE PET/CT In Breast Cancer Imaging","status":"COMPLETED","sponsor":"Celal Bayar University","startDate":"2020-11-11","conditions":["Breast Cancer"],"enrollment":16,"completionDate":"2023-09-15"},{"nctId":"NCT06159920","phase":"","title":"Evaluation of the Diagnostic and Prognostic Role of PET (PET/CT and PET/MRI) in Neuroendocrin Tumors.","status":"RECRUITING","sponsor":"IRCCS San Raffaele","startDate":"2021-10-27","conditions":["Neuroendocrine Tumors"],"enrollment":800,"completionDate":"2024-12-27"},{"nctId":"NCT05069220","phase":"EARLY_PHASE1","title":"18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2021-09-01","conditions":["Neuroendocrine Tumor","Neuroblastoma","Pheochromocytoma","Paraganglioma"],"enrollment":150,"completionDate":"2026-12"},{"nctId":"NCT05990998","phase":"PHASE1,PHASE2","title":"A Head-to-head Comparison of [68Ga]Ga-FAPI and [68Ga]Ga-TATE PET/CT in Patients With Nasopharyngeal Carcinoma: a Single-center, Prospective Study","status":"COMPLETED","sponsor":"First Affiliated Hospital of Fujian Medical University","startDate":"2022-11-20","conditions":["Tumor Positron-Emission Tomography"],"enrollment":38,"completionDate":"2023-09-01"},{"nctId":"NCT05536960","phase":"NA","title":"Dotatate to Locate Coronary Plaques at High-risk of Myocardial Infarction","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2022-09-09","conditions":["Atheroscleroses, Coronary"],"enrollment":41,"completionDate":"2023-10-06"},{"nctId":"NCT03347760","phase":"NA","title":"Pilot Study Evaluating Somatostatin Receptor's PET Imaging to Detect Inflammatory Phases of Myocarditis","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2020-07-13","conditions":["Myocarditis"],"enrollment":33,"completionDate":"2023-12-13"},{"nctId":"NCT03873870","phase":"NA","title":"68Ga-DOTATATE PET for Management of Neuroendocrine Tumors","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2019-03-28","conditions":["Neuroendocrine Tumors"],"enrollment":1916,"completionDate":"2023-04-30"},{"nctId":"NCT06155318","phase":"","title":"68Ga-DOTATOC PET for the Evaluation of Gastroenteropancreatic Neuroendocrine Tumours","status":"RECRUITING","sponsor":"IRCCS San Raffaele","startDate":"2019-09-05","conditions":["Gastroenteropancreatic Neuroendocrine Tumor"],"enrollment":300,"completionDate":"2029-05-05"},{"nctId":"NCT04040166","phase":"NA","title":"Carotid PET/MRI With DOTATATE in Patients Post Head and Neck Radiation Therapy","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2019-08-22","conditions":["Head & Neck Cancer"],"enrollment":20,"completionDate":"2021-04-15"},{"nctId":"NCT05448157","phase":"","title":"68Ga-DOTATOC Radio-Guided Surgery With β-Probe in GEP-NET","status":"UNKNOWN","sponsor":"European Institute of Oncology","startDate":"2022-05-12","conditions":["Neuroendocrine Tumor Carcinoid","Neuroendocrine Tumor of Pancreas","Gep Net"],"enrollment":20,"completionDate":"2023-12-12"},{"nctId":"NCT03623984","phase":"EARLY_PHASE1","title":"Molecular-Guided Surgery for Pancreatic and GI Neuroendocrine Cancers","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"2019-06-07","conditions":["Neuroendocrine Carcinoma of Pancreas","Carcinoid"],"enrollment":0,"completionDate":"2023-06-07"},{"nctId":"NCT03953131","phase":"PHASE1","title":"Gallium Ga 68-DOTATATE PET/CT in Predicting Tumor Growth in Patients With Meningiomas","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-01-10","conditions":["Meningioma"],"enrollment":13,"completionDate":"2023-08-30"},{"nctId":"NCT03136328","phase":"PHASE3","title":"Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan","status":"COMPLETED","sponsor":"Montefiore Medical Center","startDate":"2016-05-16","conditions":["Neuroendocrine Tumors"],"enrollment":11,"completionDate":"2017-03"},{"nctId":"NCT02150408","phase":"NA","title":"Evaluation of PET-CT Using Somatostatin Agonists Labeled With Gallium68 in Neuroendocrine Tumors","status":"COMPLETED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2014-04-22","conditions":["Gastro-Entero-Pancreatic Tumors (GEPs)"],"enrollment":35,"completionDate":"2023-04-05"},{"nctId":"NCT02186678","phase":"NA","title":"Comparison of Diagnostic Performances of 68Ga-DOTATATE PET-CT and 18F-FDOPA PET-CT in Paragangliomas and Pheochromocytomas Evaluation","status":"COMPLETED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2014-07-18","conditions":["Paragangliomas","Pheochromocytomas"],"enrollment":30,"completionDate":"2023-04-05"},{"nctId":"NCT05730634","phase":"NA","title":"The Effect of Statin Treatment on Arterial Wall Inflammation as Assessed With 68Ga-DOTATATE PET-CT","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2019-06-01","conditions":["Diabetes Mellitus, Type 2","Vascular Inflammation"],"enrollment":24,"completionDate":"2022-05-06"},{"nctId":"NCT03273712","phase":"PHASE2","title":"Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)","status":"COMPLETED","sponsor":"University of Iowa","startDate":"2017-09-29","conditions":["Neuroendocrine Tumors","Meningioma","Neuroblastoma","Medulloblastoma"],"enrollment":39,"completionDate":"2020-05-27"},{"nctId":"NCT03648073","phase":"PHASE1,PHASE2","title":"[68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2019-01-30","conditions":["Hepatocellular Carcinoma"],"enrollment":12,"completionDate":"2022-02-03"},{"nctId":"NCT03478358","phase":"PHASE1","title":"Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2017-04-30","conditions":["Neuroendocrine Tumors"],"enrollment":60,"completionDate":"2023-05-01"},{"nctId":"NCT04043377","phase":"PHASE3","title":"68Ga-DOTATATE PET-CTA Imaging for the Early Detection of Progressing Coronary Atherosclerosis","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-11-21","conditions":["Coronary Arteriosclerosis"],"enrollment":12,"completionDate":"2021-09-13"},{"nctId":"NCT00001277","phase":"PHASE2","title":"Studies of Elevated Parathyroid Activity","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"1993-12-15","conditions":["Hyperparathyroidism","Hypercalcemia","Parathyroid Neoplasm","Multiple Endocrine Neoplasia","MEN1"],"enrollment":1553,"completionDate":"2020-12-23"},{"nctId":"NCT03741517","phase":"","title":"Biomarker Study of Pancreatic Neuroendocrine Tumours","status":"UNKNOWN","sponsor":"Uppsala University","startDate":"2019-01-30","conditions":["Pancreatic Neuroendocrine Tumor"],"enrollment":40,"completionDate":"2024-12-31"},{"nctId":"NCT01869725","phase":"PHASE2","title":"Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT","status":"COMPLETED","sponsor":"Sue O'Dorisio","startDate":"2013-04-01","conditions":["Adult Medulloblastoma","Childhood Medulloblastoma","Neuroblastoma","Neuroendocrine Tumor","Somatostatinoma"],"enrollment":68,"completionDate":"2018-12-26"},{"nctId":"NCT01619865","phase":"PHASE1,PHASE2","title":"Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors","status":"COMPLETED","sponsor":"Sue O'Dorisio","startDate":"2012-02-21","conditions":["Neuroendocrine Tumors","Carcinoid Tumors","Neuroblastoma","Medulloblastoma"],"enrollment":223,"completionDate":"2017-08-27"},{"nctId":"NCT03125629","phase":"PHASE2","title":"Comparison of PET/CT vs. PET/MRI Using 2 Radiopharmaceuticals","status":"COMPLETED","sponsor":"Stanford University","startDate":"2014-05-27","conditions":["Cancer Diagnosis","Diagnostic Techniques and Procedures","Diagnostic Imaging"],"enrollment":53,"completionDate":"2020-02-05"},{"nctId":"NCT03001349","phase":"EARLY_PHASE1","title":"68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-05-16","conditions":["Meningioma","Metastatic Well Differentiated Neuroendocrine Neoplasm","Multiple Endocrine Neoplasia Type 1","Neuroendocrine Neoplasm","Somatostatin Positive Neoplastic Cells Present","Von Hippel-Lindau Syndrome"],"enrollment":4,"completionDate":"2021-02-05"},{"nctId":"NCT04017104","phase":"","title":"Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging","status":"UNKNOWN","sponsor":"British Columbia Cancer Agency","startDate":"2019-11-01","conditions":["Neuroendocrine Tumors","Prostate Cancer","Prostatic Neoplasms","Carcinoid Tumor","Paraganglioma","Neuroblastoma"],"enrollment":60,"completionDate":"2024-08-01"},{"nctId":"NCT04689893","phase":"PHASE1","title":"Application of 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET/CT in the Diagnosis and Evaluation of TIO","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-03-15","conditions":["Tumor-Induced Osteomalacia"],"enrollment":50,"completionDate":"2022-03-15"},{"nctId":"NCT02441062","phase":"PHASE2","title":"Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors","status":"COMPLETED","sponsor":"Sue O'Dorisio","startDate":"2015-09","conditions":["Neuroendocrine Tumors","Carcinoid Tumors","Neuroblastoma","Medulloblastoma"],"enrollment":122,"completionDate":"2020-01-20"},{"nctId":"NCT04622631","phase":"","title":"Using 18F- FDG,18F-DOPA and 68Ga-DOTATATE PET/CT in Detection and Evaluation of Response in Patients With NET Undergoing PRRT","status":"UNKNOWN","sponsor":"Dr. Nayruz Knaana","startDate":"2020-11","conditions":["Neuroendocrine Tumors"],"enrollment":80,"completionDate":"2023-01"},{"nctId":"NCT03549598","phase":"PHASE4","title":"d68Ga-DOTATATE PET/CT Assessment of Cardiac Sarcoidosis","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2018-07-20","conditions":["Cardiac Sarcoidosis"],"enrollment":15,"completionDate":"2019-10-02"},{"nctId":"NCT02174679","phase":"","title":"68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)","status":"NO_LONGER_AVAILABLE","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"","conditions":["Carcinoid Cancer","Neuroendocrine Tumors","Medullary Thyroid Cancer","Cancers Expressing Somatostatin Receptors"],"enrollment":0,"completionDate":""},{"nctId":"NCT03197012","phase":"EARLY_PHASE1","title":"Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor","status":"COMPLETED","sponsor":"Thomas Hope","startDate":"2017-07-01","conditions":["Neuroendocrine Tumor"],"enrollment":10,"completionDate":"2019-05-31"},{"nctId":"NCT01967537","phase":"PHASE2","title":"Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2013-10-18","conditions":["Neuroendocrine Tumors","Von Hippel-Lindau Syndrome","Hippel-Lindau Disease"],"enrollment":341,"completionDate":"2018-03-12"},{"nctId":"NCT02177773","phase":"PHASE1,PHASE2","title":"GA-68 DOTA-TOC of Somatostatin Positive Malignancies","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2014-06-23","conditions":["Neuroendocrine Tumor","Paraganglioma","Carcinoid Tumors","Neuroblastoma"],"enrollment":300,"completionDate":"2017-08-07"},{"nctId":"NCT04152928","phase":"NA","title":"Applying PET/MR in Neuroendocrine Tumors - Imaging Dynamic Processes in Both Modalities","status":"UNKNOWN","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2020-02-25","conditions":["Neuroendocrine Tumors"],"enrollment":50,"completionDate":"2022-02-25"},{"nctId":"NCT04041882","phase":"EARLY_PHASE1","title":"68Ga-DOTATATE PET/CT in Neuroendocrine Tumor","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2014-04-01","conditions":["Neuroendocrine Tumors"],"enrollment":100,"completionDate":"2022-01-30"},{"nctId":"NCT03057509","phase":"PHASE1","title":"A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2018-11","conditions":["Small Bowel Carcinoid Tumor"],"enrollment":0,"completionDate":"2021-09-30"},{"nctId":"NCT03013387","phase":"PHASE2","title":"Dosimetry Guided PRRT With 90Y-DOTATOC","status":"WITHDRAWN","sponsor":"Sue O'Dorisio","startDate":"2017-01","conditions":["Neuroendrocrine Tumors","Meningioma","Neuroblastoma","Medulloblastoma"],"enrollment":0,"completionDate":"2019-10"},{"nctId":"NCT01980732","phase":"","title":"68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors","status":"NO_LONGER_AVAILABLE","sponsor":"Andrei Iagaru","startDate":"","conditions":["Carcinoid Tumors","Islet Cell (Pancreatic NET)","Other Neuroendocrine Tumors"],"enrollment":0,"completionDate":""},{"nctId":"NCT02134639","phase":"","title":"PET-CT Imaging of Neuro-endocrine Tumors and Preliminary Clinical Evaluation","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2014-09","conditions":["Neuroendocrine Tumors"],"enrollment":20,"completionDate":"2015-01"},{"nctId":"NCT02359500","phase":"PHASE1","title":"68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)","status":"TERMINATED","sponsor":"Lale Kostakoglu","startDate":"2014-12","conditions":["Neuroendocrine Tumors","Carcinoid Tumors"],"enrollment":71,"completionDate":"2017-01-23"},{"nctId":"NCT02194452","phase":"NA","title":"Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors","status":"WITHDRAWN","sponsor":"Sue O'Dorisio","startDate":"2013-09","conditions":["Acoustic Schwannoma","Adult Anaplastic Astrocytoma","Adult Anaplastic Ependymoma","Adult Anaplastic Meningioma","Adult Anaplastic Oligodendroglioma","Adult Brain Stem Glioma","Adult Choroid Plexus Tumor","Adult Craniopharyngioma","Adult Diffuse Astrocytoma","Adult Ependymoblastoma","Adult Ependymoma","Adult Giant Cell Glioblastoma","Adult Glioblastoma","Adult Gliosarcoma","Adult Grade I Meningioma","Adult Grade II Meningioma","Adult Medulloblastoma","Adult Meningeal Hemangiopericytoma","Adult Mixed Glioma","Adult Myxopapillary Ependymoma","Adult Oligodendroglioma","Adult Papillary Meningioma","Adult Pilocytic Astrocytoma","Adult Pineal Gland Astrocytoma","Adult Pineoblastoma","Adult Pineocytoma","Adult Subependymal Giant Cell Astrocytoma","Adult Subependymoma","Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)","Childhood Choroid Plexus Tumor","Childhood Craniopharyngioma","Childhood Ependymoblastoma","Childhood Grade I Meningioma","Childhood Grade II Meningioma","Childhood Grade III Meningioma","Childhood High-grade Cerebellar Astrocytoma","Childhood High-grade Cerebral Astrocytoma","Childhood Infratentorial Ependymoma","Childhood Low-grade Cerebellar Astrocytoma","Childhood Low-grade Cerebral Astrocytoma","Childhood Medulloepithelioma","Childhood Supratentorial Ependymoma","Meningeal Melanocytoma","Newly Diagnosed Childhood Ependymoma","Recurrent Adult Brain Tumor","Recurrent Childhood Anaplastic Astrocytoma","Recurrent Childhood Anaplastic Oligoastrocytoma","Recurrent Childhood Anaplastic Oligodendroglioma","Recurrent Childhood Brain Stem Glioma","Recurrent Childhood Cerebellar Astrocytoma","Recurrent Childhood Cerebral Astrocytoma","Recurrent Childhood Diffuse Astrocytoma","Recurrent Childhood Ependymoma","Recurrent Childhood Fibrillary Astrocytoma","Recurrent Childhood Gemistocytic Astrocytoma","Recurrent Childhood Giant Cell Glioblastoma","Recurrent Childhood Glioblastoma","Recurrent Childhood Gliomatosis Cerebri","Recurrent Childhood Gliosarcoma","Recurrent Childhood Medulloblastoma","Recurrent Childhood Oligoastrocytoma","Recurrent Childhood Oligodendroglioma","Recurrent Childhood Pilocytic Astrocytoma","Recurrent Childhood Pilomyxoid Astrocytoma","Recurrent Childhood Pineoblastoma","Recurrent Childhood Pleomorphic Xanthoastrocytoma","Recurrent Childhood Protoplasmic Astrocytoma","Recurrent Childhood Subependymal Giant Cell Astrocytoma","Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor","Recurrent Childhood Visual Pathway and Hypothalamic Glioma","Recurrent Childhood Visual Pathway Glioma","Untreated Childhood Anaplastic Astrocytoma","Untreated Childhood Anaplastic Oligodendroglioma","Untreated Childhood Brain Stem Glioma","Untreated Childhood Cerebellar Astrocytoma","Untreated Childhood Cerebral Astrocytoma","Untreated Childhood Diffuse Astrocytoma","Untreated Childhood Fibrillary Astrocytoma","Untreated Childhood Gemistocytic Astrocytoma","Untreated Childhood Giant Cell Glioblastoma","Untreated Childhood Glioblastoma","Untreated Childhood Gliomatosis Cerebri","Untreated Childhood Gliosarcoma","Untreated Childhood Medulloblastoma","Untreated Childhood Oligoastrocytoma","Untreated Childhood Oligodendroglioma","Untreated Childhood Pilocytic Astrocytoma","Untreated Childhood Pilomyxoid Astrocytoma","Untreated Childhood Pineoblastoma","Untreated Childhood Pleomorphic Xanthoastrocytoma","Untreated Childhood Protoplasmic Astrocytoma","Untreated Childhood Subependymal Giant Cell Astrocytoma","Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor","Untreated Childhood Visual Pathway and Hypothalamic Glioma","Untreated Childhood Visual Pathway Glioma"],"enrollment":0,"completionDate":"2017-03"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Mayo Clinic","relationship":"Current Owner"}],"publicationCount":14,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"2025 Oct","pmid":"41281034","title":"Optimising Gallium-68 (⁶⁸Ga) DOTATATE PET/CT Reconstruction in Neuroendocrine Tumours: A Paired Comparison of Penalised-Likelihood (BSREM/Q.Clear) and Ordered Subset Expectation Maximisation Algorithms.","journal":"Cureus"},{"date":"2025 Dec","pmid":"41064857","title":"(68)Ga-DOTATATE Measurements Predict Progression of Aortic Valve Calcification in Humans.","journal":"Arteriosclerosis, thrombosis, and vascular biology"},{"date":"2024 Nov 28","pmid":"39613415","title":"Remission of longstanding metastatic paraganglioma in a patient after use of zoledronic acid.","journal":"BMJ case reports"},{"date":"2024 Oct","pmid":"39137605","title":"(68)Ga-DOTATATE PET/CT: How is it reliable in imaging of cases having clinical suspicion of insulinomas?","journal":"European journal of radiology"},{"date":"2024 Jun","pmid":"39006730","title":"Occult Pancreatic Neuroendocrine Tumor Presenting as Carcinoid Syndrome.","journal":"Cureus"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"Gallium Ga 68-DOTATATE","companyName":"Mayo Clinic","companyId":"mayo-clinic","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gallium Ga 68-DOTATATE is used in PET/CT scans to study and diagnose various conditions, including Neuroendocrine Tumors, Carcinoid Tumors, Medullary Thyroid Carcinoma, and Tumor-Induced Osteomalacia. It is also being investigated for its potential use in Breast Cancer imaging, as seen in a prospective study comparing it to 18F FDG PET/CT.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":13,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}